Skip to search formSkip to main contentSkip to account menu

vanoxerine

Known as: 1-(2 (bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine, 1-(2-(bis(p-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine, vanoxeamine 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Dopamine Uptake InhibitorsPiperazines

Narrower (2)

GBR 12909I 893

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Tackling antimicrobial resistance through two novel methods: repurposing vanoxerine as a novel anti-tubercular drug; and silencing virulence in Pseudomonas aeruginosa through inhibition of PqsR
The antimicrobial resistance crisis is one which will persist and worsen without intervention. This thesis looks to explore two… 
2014
2014
Synthetic method for vanoxerine
The invention discloses a new synthetic method for vanoxerine. The method employs 1-bromo-3-phenylpropane and 4… 
2011
2011
Pharmaceutical compositions containing vanoxerine
Disclosed embodiments are related to compositions of vanoxerine (GBR 12909), including compositions of vanoxerine and one or more… 
2011
2011
Pharmaceutical compositions containing the vanoxerine
2007
2007
Concurrent appearance of vanoxerine, mCPP and 'wormazine' on the Belgian market: a case study
Vanoxerine (GBR-12909) is a high-affinity dopamine reuptake inhibitor (fig.1). Synthesized in the late 1970s, vanoxerine was…